Literature DB >> 34806561

Hydrolytic activity of KPC-producing Klebsiella pneumoniae clinical isolates.

Vincent H Tam1, Cole S Hudson1, Paul R Merlau1, Ryan K Shields2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34806561      PMCID： PMC9124231          DOI： 10.1080/1120009X.2021.2004363

Source DB:  PubMed          Journal:  J Chemother        ISSN： 1120-009X            Impact factor:   2.385


× No keyword cloud information.
  4 in total

1.  Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae.

Authors:  Henrietta Abodakpi; Kai-Tai Chang; Song Gao; Ana María Sánchez-Díaz; Rafael Cantón; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

2.  Prevalence of extended-spectrum beta-lactamase and carbapenemase-producing bloodstream isolates of Klebsiella pneumoniae in a tertiary care hospital.

Authors:  Henrietta Abodakpi; Kai-Tai Chang; Ana María Sánchez Díaz; Rafael Cantón; Todd M Lasco; Katrina Chan; Amelia K Sofjan; Vincent H Tam
Journal:  J Chemother       Date:  2017-11-10       Impact factor: 1.714

Review 3.  New β-Lactam-β-Lactamase Inhibitor Combinations.

Authors:  Dafna Yahav; Christian G Giske; Alise Grāmatniece; Henrietta Abodakpi; Vincent H Tam; Leonard Leibovici
Journal:  Clin Microbiol Rev       Date:  2020-11-11       Impact factor: 26.132

4.  Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.

Authors:  Ryan K Shields; Liang Chen; Shaoji Cheng; Kalyan D Chavda; Ellen G Press; Avin Snyder; Ruchi Pandey; Yohei Doi; Barry N Kreiswirth; M Hong Nguyen; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.